136 related articles for article (PubMed ID: 37717256)
1. Factors associated with daily use of benzodiazepines/tranquilizers and opioids among people who use drugs.
Kozak Z; Urquhart GJ; Rouhani S; Allen ST; Park JN; Sherman SG
Am J Addict; 2024 Jan; 33(1):83-91. PubMed ID: 37717256
[TBL] [Abstract][Full Text] [Related]
2. Daily opioid and stimulant co-use and nonfatal overdoses in the context of social disadvantage: Findings on marginalized populations.
Jones AA; Schneider KE; Tobin KE; O'Sullivan D; Latkin CA
J Subst Use Addict Treat; 2023 Aug; 151():208986. PubMed ID: 36822268
[TBL] [Abstract][Full Text] [Related]
3. Correlates of opioid and benzodiazepine co-prescription among people living with HIV in British Columbia, Canada: A population-level cohort study.
Parent S; Nolan S; Fairbairn N; Ye M; Wu A; Montaner J; Barrios R; Ti L;
Int J Drug Policy; 2019 May; 67():52-57. PubMed ID: 30897373
[TBL] [Abstract][Full Text] [Related]
4. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).
Allen ST; Schneider KE; Rouhani S; White RH; Morris M; Owczarzak J; Sherman SG
Ann Med; 2023 Dec; 55(1):2196435. PubMed ID: 37078710
[TBL] [Abstract][Full Text] [Related]
5. Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids.
Brown JL; Cochran G; Bryan MA; Charron E; Winhusen TJ
Subst Abus; 2022; 43(1):1110-1115. PubMed ID: 35499399
[No Abstract] [Full Text] [Related]
6. Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
Ali SA; Shell J; Harris R; Bedder M
Harm Reduct J; 2023 Oct; 20(1):144. PubMed ID: 37798673
[TBL] [Abstract][Full Text] [Related]
7. An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines.
Zaman T; Rife TL; Batki SL; Pennington DL
Subst Abus; 2018; 39(4):441-448. PubMed ID: 29595408
[TBL] [Abstract][Full Text] [Related]
8. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
[TBL] [Abstract][Full Text] [Related]
9. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
[TBL] [Abstract][Full Text] [Related]
10. Identifying pathways to recent non-fatal overdose among people who use opioids non-medically: How do psychological pain and unmet mental health need contribute to overdose risk?
Tomko C; Schneider KE; Rouhani S; Urquhart GJ; Nyeong Park J; Morris M; Sherman SG
Addict Behav; 2022 Apr; 127():107215. PubMed ID: 34953432
[TBL] [Abstract][Full Text] [Related]
11. More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD.
Dayton L; Gicquelais RE; Tobin K; Davey-Rothwell M; Falade-Nwulia O; Kong X; Fingerhood M; Jones AA; Latkin C
PLoS One; 2019; 14(11):e0224686. PubMed ID: 31697736
[TBL] [Abstract][Full Text] [Related]
12. Recent Use of Synthetic Cannabinoids, Synthetic Opioids, and Other Psychoactive Drug Groups among High-risk Drug Users.
Shapira B; Berkovitz R; Rosca P; Neumark Y
J Psychoactive Drugs; 2020; 52(4):334-343. PubMed ID: 32345134
[TBL] [Abstract][Full Text] [Related]
13. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.
Gomes T; Juurlink DN; Antoniou T; Mamdani MM; Paterson JM; van den Brink W
PLoS Med; 2017 Oct; 14(10):e1002396. PubMed ID: 28972983
[TBL] [Abstract][Full Text] [Related]
14. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania.
Pizzicato LN; Johnson CC; Viner KM
Subst Abus; 2020; 41(3):301-306. PubMed ID: 31644397
[No Abstract] [Full Text] [Related]
15. Physician Renewal of Chronically Prescribed Controlled Substances Based on Urine Drug Test Results.
Hosain F; Lee J; Ata A; Bhullar RK; Chang AK
J Prim Care Community Health; 2019; 10():2150132719883632. PubMed ID: 31646927
[No Abstract] [Full Text] [Related]
16. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
17. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
18. Medical use, non-medical use and use disorders of benzodiazepines and prescription opioids in adults: Differences by insurance status.
Tardelli VS; Fidalgo TM; Santaella J; Martins SS
Drug Alcohol Depend; 2019 Nov; 204():107573. PubMed ID: 31568936
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
[TBL] [Abstract][Full Text] [Related]
20. Beliefs about the consequences of using benzodiazepines among persons with opioid use disorder.
Stein MD; Anderson BJ; Kenney SR; Bailey GL
J Subst Abuse Treat; 2017 Jun; 77():67-71. PubMed ID: 28476275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
